help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miwa, I.
Right arrow Articles by Taniguchi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miwa, I.
Right arrow Articles by Taniguchi, S.
Endocrinology Vol. 141, No. 8 2767-2772
Copyright © 2000 by The Endocrine Society


ARTICLES

Inhibition of Glucose-Induced Insulin Secretion by 4-Hydroxy-2-Nonenal and Other Lipid Peroxidation Products1

Ichitomo Miwa, Noriko Ichimura, Michiharu Sugiura, Yoshiki Hamada and Shigeki Taniguchi

Departments of Pathobiochemistry (I.M., N.I., S.T.) and Organic Manufacturing (M.S., Y.H.), Faculty of Pharmacy, Meijo University, Nagoya 468-8503, Japan

Address all correspondence and requests for reprints to: Ichitomo Miwa, Ph.D., Department of Pathobiochemistry, Faculty of Pharmacy, Meijo University, Tempaku-ku, Nagoya 468-8503, Japan. E-mail: miwaichi{at}meijo-u.ac.jp


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Lipid peroxidation due to oxidative stress is accelerated under hyperglycemic conditions such as diabetes mellitus. The effect of 4-hydroxy-2-nonenal (HNE) and other lipid peroxidation products on the ability of isolated rat pancreatic islets to secrete insulin was examined in this study. HNE concentration- and time-dependently deteriorated glucose-induced insulin secretion: insulin secretion was decreased by 50% when measured after incubation of islets with 100 µM HNE for 1 h. Other lipid peroxidation products, e.g. 2-hexenal and 2-butenal, also inhibited glucose-induced insulin secretion. HNE at 100 µM lowered {alpha}-ketoisocaproate-induced insulin secretion, whereas leucine-induced insulin secretion was stimulated. Insulin secretion induced by 10 mM glyceraldehyde was slightly decreased by HNE. On the other hand, HNE severely decreased insulin secretion induced by 10 mM glyceraldehyde and 2.8 mM glucose. Glucose utilization and glucose oxidation were significantly lowered in islets treated with HNE. The amounts of fructose 1,6-bisphosphate and dihydroxyacetone phosphate in islets were decreased by treatment with HNE, whereas the amount of fructose 6-phosphate was increased. Our study indicates that HNE and other lipid peroxidation products impair insulin secretion induced by glucose probably through affecting both the glycolytic pathway and the citric acid cycle.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
ACCELERATED GENERATION of reactive oxygen species has been shown to occur in diabetes mellitus in association with hyperglycemia (1, 2). The reaction of free radicals with membrane lipids leads to the formation of lipid peroxidation products including several aldehydic compounds. One of the most abundant and highly toxic lipid aldehydes is 4-hydroxy-2-nonenal (HNE) (3). The alkenal, having a highly reactive {alpha}, ß unsaturated double bond, spontaneously forms Michael adducts with sulfhydryl groups of glutathione and proteins. HNE also reacts with histidine and lysine residues of proteins to form Michael adducts (4). The alkenal thus alters the catalytic and structural properties of proteins (5, 6) and induces adverse biological effects, such as toxicity toward mammalian cells, blockade of cell proliferation, and inhibition of the synthesis of DNA, RNA, and protein (3, 7).

Recently, it was reported that the gene expression of various antioxidant enzymes, i.e. superoxide dismutase, catalase, and glutathione peroxidase, was substantially lower in mouse pancreatic islets than in various other tissues (8). This fact suggests that pancreatic islets would be more vulnerable to oxidative stress than other tissues. Another paper reported that cytokines might damage islet ß-cells by inducing oxygen free radical generation, lipid peroxidation, and consequently the formation of aldehydes such as HNE, hexanal, and malondialdehyde in the islet cells (9). These findings taken together with the above considerations raise the possibility that HNE may affect insulin secretion from pancreatic islets. In this study we examined the effect of HNE and other aldehydes on insulin secretion induced by glucose and other secretagogues.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Materials
HNE was synthesized as described previously (10) and stored as an ethanol solution (200 mM) at -35 C. To prepare an aqueous solution of HNE, we evaporated a sample of the ethanol stock solution at 30 C under N2 gas and dissolved the residue in distilled water. The exact concentration was estimated spectrophotometrically at 223 nm ({epsilon} = 13,750 liters/mol·cm), and the solution was then brought to concentrations of 25–100 µM by the addition of Krebs-Ringer bicarbonate (KRB) buffer (pH 7.4). KRB buffer contained 118 mM NaCl, 4.7 mM KC1, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, and 24.2 mM NaHCO3 and was equilibrated with 5% CO2/95% O2.

KRB buffer containing 2 mg/ml BSA was used as a medium for the incubation of pancreatic islets with HNE. We found that the incubation markedly decreased the HNE concentration because of the covalent-bond formation between HNE and BSA. Therefore, we prepared HNE-treated BSA. HNE (20 µmol) and BSA (0.4 g) were dissolved in 10 ml KRB buffer containing 2.8 mM glucose and incubated for 2 h at 37 C under an atmosphere of 5% CO2/95% O2. The solution was thoroughly dialyzed against the same buffer and then centrifuged for 10 min at 10,000 x g at 4 C to eliminate sediments. The supernatant was used as a solution of HNE-treated BSA. When 100 µM HNE was incubated in KRB buffer containing 2 mg/ml untreated BSA for 1 h at 37 C, the HNE concentration decreased to 50 µM. On the other hand, the use of HNE-treated BSA instead of untreated BSA clearly reduced the loss of HNE; the HNE concentration after incubation was 85 µM.

Malondialdehyde was prepared by hydrolysis of malonaldehyde bis(dimethylacetal) in 1 M HC1 for 10 min at 30 C. The concentration of malondialdehyde was estimated at 245 nm ({epsilon} = 13,700 liters/mol·cm). Just before use, the acidic solution was neutralized with 2 M NaHCO3.

2-Nonenal, 2-octenal, 2-hexenal, and D-glyceraldehyde were obtained from Aldrich Japan (Tokyo, Japan). D-[5-3H]glucose, D-[U-14C]glucose, [3H]water, and [14C]sodium bicarbonate were purchased from NEN Life Science Products (Boston, MA). Hexanal, calf thymus DNA, and sodium {alpha}-ketoisocaproate came from Sigma (St. Louis, MO). Malonaldehyde bis(dimethylacetal) and 2-butenal were purchased from Tokyo Kasei (Tokyo, Japan). H33258 was obtained from Calbiochem (La Jolla, CA). Hyamine came from Packard (Meriden, CT).

Rats were housed in a room maintained at 23 C with a fixed 12-h light, 12-h dark cycle and were given free access to rat chow and water. Experimental protocols were approved by the animal use committee of the Faculty of Pharmacy, Meijo University.

Incubation of islets and measurement of insulin secretion
Pancreatic islets were isolated from female Wistar rats (weighing 300–350 g; Clea Japan, Tokyo, Japan) according to the method described previously (11). Batches of 5 islets were treated with aldehyde (e.g. HNE and 2-hexanal) for 1 h at 37 C in 1 ml KRB buffer supplemented with 5 mM glucose and 2 mg/ml HNE-treated BSA. The islets were washed once with KRB buffer containing 2.8 mM glucose and 2 mg/ml BSA at room temperature, and then incubated for 1 h at 37 C in 1 ml KRB buffer supplemented with 2 mg/ml BSA together with 20 mM glucose, 10 mM D-glyceraldehyde, 10 mM D-glyceraldehyde plus 2.8 mM glucose, 15 mM {alpha}-ketoisocaproate, or 15 mM L-leucine. All incubations were performed in an atmosphere of 5% CO2-95% O2. In control experiments, the first incubation of islets was performed in the absence of aldehyde. Of the aldehydes used, 2-nonenal and 2-octenal were dissolved in ethanol and diluted to yield a final solvent concentration of 0.1%. Insulin in the medium obtained after the second incubation was assayed as described previously (12). The basal insulin secretion induced in the presence of 2.8 mM glucose was 19 ± 1 µU/h·islet (mean ± SEM of 25 determinations). The insulin secretion values were expressed by subtraction of basal secretion. In this article 1 determination refers to 1 incubation well containing 5 islets.

Measurement of glucose utilization
Glucose utilization by islets was determined by measuring the formation of 3H2O from D-[5-3H]glucose (13). Briefly, batches of 10 islets were incubated for 1 h at 37 C in the presence or absence of 100 µM HNE, washed with KRB buffer containing 2.8 mM glucose and 2 mg/ml BSA, and again incubated for 1 h in 400 µl KRB buffer containing glucose (2.8 or 20 mM) and 2 mg/ml BSA as well as 1.6 µCi D-[5-3H]glucose. After the second incubation, 20 µl 3 M HCl and 50 µl ethanol were added to stop metabolism, and then a piece of filter paper was put into each microtube. The microtubes were placed in 20-ml glass scintillation vials that contained 1 ml purified water. The vials were stoppered and kept at 30 C for 24 h. 3H2O standard was treated in the same way to correct for incomplete equilibration during the diffusion step. Radioactivity in the purified water was determined.

Measurement of glucose oxidation
Glucose oxidation by islets was determined by measuring the formation of 14CO2 from D-[U-14C]glucose (14). Briefly, batches of 8 islets were incubated for 1 h at 37 C in the presence or absence of 100 µM HNE, washed once, and again incubated for 1 h in 300 µl KRB buffer containing glucose (2.8 or 20 mM) and 2 mg/ml BSA as well as 0.6 µCi D-[U-14C]glucose. After the second incubation, 15 µl 3 M HCl were added to each microtube to stop metabolism and to liberate 14CO2 from the medium. The microtubes were placed in 20-ml glass scintillation vials that contained 0.6 ml hyamine, and then the vials were stoppered and kept at room temperature for 2 h to permit absorption of 14CO2. NaH14CO3 standard was treated in the same way to correct for incomplete 14CO2 absorption. Radioactivity in the hyamine was determined.

Measurement of glycolytic intermediates
Batches of 40–50 islets were incubated for 1 h at 37 C in the presence or absence of 100 µM HNE, washed once, and again incubated for 1 h in 5 ml KRB buffer containing glucose (2.8 or 20 mM) and 2 mg/ml BSA. After removal of the medium, the islets were quickly washed with ice-cold KRB buffer and then sonicated in 70 µl 0.4 M HClO4. The sonicate was centrifuged, and the supernatant was neutralized with 200 mM HEPES-NaOH buffer (pH 7.0) and 1 SC K2CO3. After centrifugation of the neutralized solution, the supernatant obtained was analyzed for glycolytic intermediates as described previously (15).

Measurement of enzyme activities
Pancreatic islets were incubated in the presence or absence of 100 µM HNE for 1 h at 37 C in 1 ml KRB buffer containing 5 mM glucose and 2 mg/ml HNE-treated BSA. The islets were washed with the medium used for their homogenization. The preparation of islet extracts and the assay of glucokinase and hexokinase activities were performed as described previously (16). The 6-phosphofructokinase (PFK) and glyceraldehyde-3-phosphate dehydrogenase activities in the islet extracts were assayed as described by Trus et al. (17) and Laychock (18), respectively.

Assay of DNA
The content of DNA in homogenates of pancreatic islets was assayed by fluorometry according to the method of Labarca and Paigen (19).

Statistical analysis
The statistical analyses were performed by the method of Dunnett with the level of significance at P < 0.05.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Treatment of pancreatic islets with HNE for 1 h concentration dependently decreased glucose-induced insulin secretion measured after the treatment (Fig. 1Go). In a treatment-time study, glucose-induced insulin secretion was significantly decreased when islets were treated with 100 µM HNE for more than 15 min (Fig. 2Go).



View larger version (12K):
[in this window]
[in a new window]
 
Figure 1. Effect of HNE concentration on glucose-induced insulin secretion. Pancreatic islets were incubated with the indicated concentrations of HNE for 1 h at 37 C and then assayed for insulin secretion induced by 20 mM glucose. Values are the mean ± SEM of 20–26 determinations. The control value was 228 ± 7 µU/h·islet. *, P < 0.01; **, P < 0.001 (compared with the control).

 


View larger version (12K):
[in this window]
[in a new window]
 
Figure 2. Effect of HNE treatment time on inhibition of glucose-induced insulin secretion. Pancreatic islets were incubated in the presence or absence of 100 µM HNE for the indicated periods at 37 C and then assayed for insulin secretion induced by 20 mM glucose. Values are the mean ± SEM of 10–12 determinations. The control values at 15, 30, and 60 min were 350 ± 7, 288 ± 4, and 235 ± 9 µU/h·islet, respectively. *, P < 0.001 (compared with the control).

 
Aldehydic lipid peroxidation products other than HNE were also tested for their deteriorating effects on glucose-induced insulin secretion at a concentration of 100 µM. 2-Alkenals significantly decreased insulin secretion, whereas alkanals, e.g. malondialdehyde and hexanal, did not affect insulin secretion (Table 1Go).


View this table:
[in this window]
[in a new window]
 
Table 1. Inhibitory effects of various aldehydes on glucose-induced insulin secretion

 
HNE at 100 µM did not decrease insulin secretion induced by leucine; rather, it increased the secretion (Fig. 3Go). In contrast, {alpha}-ketoisocaproate-induced insulin secretion was significantly decreased by treatment with the aldehyde.



View larger version (32K):
[in this window]
[in a new window]
 
Figure 3. Effect of HNE on insulin secretion induced by leucine or {alpha}-ketoisocaproate. Pancreatic islets were incubated in the presence () or absence ({square}) of 100 µM HNE for 1 h at 37 C and then assayed for insulin secretion induced by 15 mM leucine (Leu) or 15 mM {alpha}-ketoisocaproate (KIC). Values are the mean ± SEM of 10 determinations. The control values for leucine- and {alpha}-ketoisocaproate-induced insulin secretion were 60 ± 3 and 112 ± 3 µU/h·islet, respectively. *, P < 0.0001 (compared with the untreated group).

 
In agreement with earlier reports (20, 21), glucose at a low concentration (2.8 mM) strongly potentiated 10 mM glyceraldehyde-induced insulin release (see Fig. 4Go). Insulin secretion induced by glyceraldehyde alone was significantly decreased by 50 and 100 µM HNE, but the decrease was only about 15% at either concentration (Fig. 4Go). On the contrary, the secretion induced by a mixture of glucose and glyceraldehyde was markedly decreased by treatment of islets with 50 or 100 µM HNE. In this case, the dependency of the decrease on the HNE concentration was quite similar to that (Fig. 1Go) seen for glucose-induced insulin secretion.



View larger version (14K):
[in this window]
[in a new window]
 
Figure 4. Effect of HNE concentration on insulin secretion induced by glyceraldehyde or glyceraldehyde plus glucose. Pancreatic islets were incubated with the indicated concentrations of HNE for 1 h at 37 C and then assayed for insulin secretion induced by 10 mM glyceraldehyde (•) or by 10 mM glyceraldehyde plus 2.8 mM glucose ({circ}). Values are the mean ± SEM of 14–16 determinations. The control values for insulin secretion induced by glyceraldehyde and by glyceraldehyde plus glucose were 96 ± 4 and 210 ± 16 µU/h·islet, respectively. +, P < 0.05; *, P < 0.01; **, P < 0.001 (compared with the control).

 
Next, we examined the effect of HNE on glucose utilization, glucose oxidation, and glycolytic intermediate levels in islets. Exposure of islets to 100 µM HNE for 1 h resulted in inhibition of both glucose utilization (Fig. 5Go) and glucose oxidation (Fig. 6Go) measured in the presence of 20 mM glucose. HNE treatment decreased the amounts of fructose 1,6-bisphosphate and dihydroxyacetone phosphate in islets incubated with 20 mM glucose, on the one hand, and increased the amount of fructose 6-phosphate, on the other hand (Fig. 7Go).



View larger version (26K):
[in this window]
[in a new window]
 
Figure 5. Effect of HNE on glucose utilization in islets. Pancreatic islets were incubated in the presence () or absence ({square}) of 100 µM HNE for 1 h at 37 C and then assayed for glucose utilization in the presence of 2.8 or 20 mM glucose. Values are the mean ± SEM of 6 or 7 determinations. *, P < 0.01; **, P < 0.001 (compared with the untreated group).

 


View larger version (26K):
[in this window]
[in a new window]
 
Figure 6. Effect of HNE on glucose oxidation in islets. Pancreatic islets were incubated in the presence () or absence ({square}) of 100 µM HNE for 1 h at 37 C and then assayed for glucose oxidation in the presence of 2.8 or 20 mM glucose. Values are the mean ± SEM of 6 determinations. *, P < 0.001 (compared with the untreated group).

 


View larger version (30K):
[in this window]
[in a new window]
 
Figure 7. Effect of HNE on glycolytic intermediate levels in islets. Pancreatic islets were incubated in the presence or absence of 100 µM HNE for 1 h at 37 C, washed once, and again incubated for 1 h in the presence of 2.8 or 20 mM glucose. Islet glycolytic intermediates were assayed enzymatically. Values are the mean ± SEM of 6 determinations. *, P < 0.05; **, P < 0.005 (compared with the untreated group).

 
We also examined the effect of HNE on various glycolytic enzymes, i.e. glucokinase (22), hexokinase (22), PFK (22), and glyceraldehyde-3-phosphate dehydrogenase (23), that are thought to be relevant to glucose-induced insulin secretion, as HNE was shown to be capable of decreasing insulin secretion induced in the presence of glucose. As shown in Table 2Go, none of the enzymes tested was affected by treatment of islets with 100 µM HNE for 1 h.


View this table:
[in this window]
[in a new window]
 
Table 2. Effect of HNE on activities of some glycolytic enzymes

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The level of HNE in tissues and body fluids of normal animals has been reported to range from 0.5–5 nmol/g or ml (24, 25, 26). Esterbauer et al. (3) suggested, however, that tissue HNE concentrations can be increased locally in the vicinity of peroxidizing membranes up to millimolar levels. Recently, in the ventricular fluid of patients with Alzheimer’s disease, HNE concentrations as high as 120 µM have been reported (27). Besides, the HNE content in rat pancreatic islets incubated for 36 h in RPMI 1640 medium containing 11 mM glucose was reported to be 0.07 pmol/islet (9): the islet HNE concentration was calculated to be 23–35 µM, provided that the mean volume of rat islets was 2–3 nl (28). It is probable that the tissue HNE concentration is higher under the diabetic than under the normal condition because of the higher oxidative stress in the former. These findings and considerations indicate that the HNE concentrations (<=100 µM) used in this study are likely to occur in pancreatic islets at least under diabetic conditions, which strongly suggests that the HNE inhibition of glucose-induced insulin secretion takes place in vivo.

All of the aldehydes listed in Table 1Go are known to be produced as lipid peroxidation products (24, 29, 30). Table 1Go illustrates that some alkenals among lipid peroxidation products, in addition to HNE, act to impair glucose-induced insulin secretion. It should be noted that shorter chain alkenals, 2-hexenal and 2-butenal, were more potent than longer chain ones, 2-nonenal and 2-octenal. The concentration dependency of the inhibitory potency of 2-hexenal and 2-butenal was quite similar to that of HNE (data not shown).

The widely accepted mechanism for glucose-induced insulin secretion is that the metabolism of glucose via the glycolytic pathway and the citric acid cycle leads to an increase in the ATP/ADP ratio, resulting in ß-cell depolarization induced by inhibition of ATP-sensitive K+ channels and in subsequent activation of voltage-dependent Ca2+ channels (31, 32). The rise in the intracellular Ca2+ concentration is thought to play a role in insulin release through activation of protein kinases that interact with components of the secretory machinery (33). {alpha}-Ketoisocaproate is oxidized via the citric acid cycle to produce ATP after its conversion to acetyl-coenzyme A and is thought to stimulate insulin secretion by the mechanism common to islet fuels including glucose (34). Leucine, in contrast to its deamination product {alpha}-ketoisocaproate, is believed to stimulate insulin secretion by two intramitochondrial mechanisms: firstly, the catabolism of leucine itself (35, 36), and secondly, the allosteric activation of glutamate dehydrogenase resulting in an increase in the formation of {alpha}-ketoglutarate, one of the intermediates of the citric acid cycle, from glutamate (37, 38). We recently found that glyceraldehyde not only stimulates insulin secretion via metabolism through the glycolytic pathway and the citric acid cycle after its phosphorylation, but also induces the activation of phospholipase C by glyceraldehyde 3-phosphate, a phosphorylation product of the triose, resulting in the stimulation of insulin secretion without the closure of ATP-sensitive K+ channels (15). The mechanism for potentiation of glyceraldehyde-induced insulin secretion by glucose is not yet known, although glucose metabolism has been shown to be responsible for the potentiation (21).

The marked inhibition of insulin secretion induced by glucose and by glyceraldehyde plus glucose implies that some step(s) responsible for glucose-induced insulin secretion is susceptible to the action of HNE. The data that HNE only slightly decreased glyceraldehyde-induced insulin secretion and increased leucine-induced insulin secretion suggest that the inhibitory effect of the aldehyde on distal secretion steps, including ß-cell depolarization, Ca2+ influx, and subsequent events, is marginal, if any. The same data are also likely to exclude the possibility that the inhibitory effect of HNE on glucose-induced insulin secretion was due to a nonspecific toxic effect on pancreatic islets.

The attenuation by HNE of islet glucose utilization in the presence of 20 mM glucose is indicative that the glycolytic pathway is affected by the aldehyde. The citric acid cycle would also be one of the possible targets of HNE, because the compound severely impaired {alpha}-ketoisocaproate-induced insulin secretion. An appreciable decrease in islet glucose oxidation by HNE would be a demonstration that the glycolytic pathway, the citric acid cycle, or both are the action sites of the aldehyde. We do not have any proper explanation for the mechanism(s) of the potentiation of leucine-induced insulin secretion by HNE. It also remains to be answered whether the HNE potentiation of leucine-induced insulin secretion is biologically meaningful. Less marked inhibition of glyceraldehyde-induced insulin secretion may indicate that the machinery for stimulation of insulin secretion through the activation of phospholipase C by glyceraldehyde 3-phosphate is kept intact in islets treated with HNE.

The decrease in fructose 1,6-bisphosphate and dihydroxyacetone phosphate contents in concord with the increase in fructose 6-phosphate content by treatment of islets with HNE strongly suggests that the aldehyde affects the PFK step in the glycolytic pathway, but not the glucose phosphorylation step. Contrary to these data, islet PFK activity was not decreased by HNE treatment. The PFK activity shown in Table 1Go, however, was assayed in the presence of 2 mM AMP (an allosteric activator of the enzyme). It is possible that the HNE-induced change in intracellular levels of allosteric effectors, e.g. citric acid and AMP, may decrease the activity of PFK.

It has been suggested that whatever defect, e.g. insulin resistance or impaired insulin secretion, initiates the disturbance in glucose metabolism, it will be followed by worsening of hyperglycemia (39). It seems worthwhile to investigate whether the impairment of insulin secretion by HNE and other lipid peroxidation products is involved in such a vicious cycle responsible for the development of type 2 diabetes, because hyperglycemia causes an increase in oxidative stress and the subsequent acceleration of lipid peroxidation.

During the course of the present study, Ihara et al. reported the presence of HNE-protein adducts in pancreatic islets (40). They stated that quantitative immunohistochemical analyses with specific antibodies revealed higher levels of HNE- modified proteins as well as 8-hydroxy-2'-deoxyguanosine (a marker for oxidative stress) in the pancreatic ß-cells of GK rats, a model of type 2 diabetes, than in the control Wistar rats, with the levels increasing proportionally with age and fibrosis of the pancreatic islets. This observation is compatible with the view that HNE and other lipid peroxidation products are implicated in the impairment of insulin secretion in diabetic animals and subjects.

In summary, we have demonstrated for the first time that lipid peroxidation products, HNE and other aldehydes, at concentrations likely to occur in tissues impair insulin secretion induced by glucose. The present study suggests the possibility that lipid peroxidation products formed by oxidative stress due to hyperglycemia in diabetes are involved in the worsening of glucose-induced insulin secretion in type 2 diabetes.


    Footnotes
 
1 This work was supported in part by a grant-in-aid (to I.M.) from the High-Tech Research Center Project of the Ministry of Education, Science, Sports, and Culture of Japan. Back

Received June 29, 1999.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Oberley LW 1988 Free radicals and diabetes. Free Radic Biol Med 5:113–124[CrossRef][Medline]
  2. Giugliano D, Ceriello A, Paolisso G 1996 Oxidative stress and diabetic vascular complications. Diabetes Care 19:257–267[Abstract]
  3. Esterbauer H, Schaur RJ, Zoller H 1991 Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde, and related aldehydes. Free Radic Biol Med 11:81–128[CrossRef][Medline]
  4. Uchida K, Szweda KI, Chae H-Z, Stadtman ER 1993 Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc Natl Acad Sci USA 90:8742–8746[Abstract/Free Full Text]
  5. Uchida K, Stadtman ER 1993 Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J Biol Chem 268:6388–6393[Abstract/Free Full Text]
  6. Bestervelt LL, Vaz ADN, Coon MJ 1995 Inactivation of ethanol-inducible cytochrome P450 and other microsomal P450 isozymes by trans-4-hydroxy-2-nonenal, a major product of membrane lipid peroxidation. Proc Natl Acad Sci USA 92:3764–3768[Abstract/Free Full Text]
  7. Esterbauer H 1993 Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 57:779S–786S
  8. Lenzen S, Drinkgern J, Tiedge M 1996 Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 20:463–466[CrossRef][Medline]
  9. Suarez-Pinzon WL, Strynadka K, Rabinovitch A 1996 Destruction of rat pancreatic islet ß-cells by cytokines involves the production of cytotoxic aldehydes. Endocrinology 137:5290–5296[Abstract]
  10. Rees MS, van Kujik FJGM, Stephens RJ, Mundy BP 1993 Synthesis of deuterated 4-hydroxyalkenals. Syn Commun 23:757–763
  11. Miwa I, Murata T, Mitsuyama S, Okuda J 1990 Participation of glucokinase inactivation in inhibition of glucose-induced insulin secretion by 2-cyclohexen-1-one. Diabetes 39:1170–1176[Abstract]
  12. Murata T, Miwa I, Toyoda Y, Okuda J 1993 Inhibition of glucose-induced insulin secretion through inactivation of glucokinase by glyceraldehyde. Diabetes 42:1003–1009[Abstract]
  13. Miwa I, Murata T, Okuda J 1991 {alpha}- and ß-anomeric preference of glucose-induced insulin secretion at physiological and higher glucose concentrations, respectively. Biochem Biophys Res Commun 180:709–715[CrossRef][Medline]
  14. Ashcroft SJH, Hedeskov CJ, Randle PJ 1970 Glucose metabolism in mouse pancreatic islets. Biochem J 118:143–154[Medline]
  15. Taniguchi S, Okinaka M, Tanigawa K, Miwa I 2000 Difference in mechanism between glyceraldehyde- and glucose-induced insulin secretion from isolated rat pancreatic islets. J Biochem 127:289–295[Abstract/Free Full Text]
  16. Miwa I, Mita Y, Murata T, Okuda J, Sugiura M, Hamada Y, Chiba T 1994 Utility of 3-O-methyl-N-acetyl-D-glucosamine, an N-acetylglucosamine kinase inhibitor, for accurate assay of glucokinase in pancreatic islets and liver. Enzyme Prot 48:135–142[Medline]
  17. Trus MD, Zawalich WS, Burch PT, Berner DK, Weill VA, Matschinsky FM 1981 Regulation of glucose metabolism in pancreatic islets. Diabetes 30:911–922[Abstract]
  18. Laychock SG 1996 Modulation of glyceraldehyde-3-phosphate dehydrogenase activity in isolated pancreatic islets. Biochem Pharmacol 52:793–799[CrossRef][Medline]
  19. Labarca C, Paigen K 1980 A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102:344–352[CrossRef][Medline]
  20. Ashcroft SJH, Weerasinghe LCC, Randle PJ 1973 Interrelationship of islet metabolism, adenosine triphosphate content and insulin release. Biochem J 132:223–231[Medline]
  21. Asanuma N, Aizawa T, Sato Y, Schermerhorn T, Komatsu M, Sharp GWG, Hashizume K 1997 Two signaling pathways, from the upper glycolytic flux and from the mitochondria, converge to potentiate insulin release. Endocrinology 138:751–755[Abstract/Free Full Text]
  22. Meglasson MD, Matschinsky FM 1984 New perspectives on pancreatic islet glucokinase. Am J Physiol 246:E1–E13
  23. Dukes ID, McIntyre MS, Mertz RJ, Philipson LH, Roe MW, Spencer B, Worley III JF 1994 Dependence on NADH produced during glycolysis for ß-cell glucose signaling. J Biol Chem 269:10979–10982
  24. Esterbauer H, Zollner H 1989 Methods for determination of aldehydic lipid peroxidation products. Free Radic Biol Med 7:197–203[CrossRef][Medline]
  25. Barrera G, Brossa O, Fazio VM, Farace MG, Paradisi L, Gravela E, Dianzani MU 1991 Effects of 4-hydroxynonenal, a product of lipid peroxidation, on cell proliferation and ornithine decarboxylase activity. Free Radic Res Commun 14:81–89[Medline]
  26. Siems WG, Grune T, Esterbauer H 1995 4-Hydroxynonenal formation during ischemia and reperfusion of rat small intestine. Life Sci 57:785–789[CrossRef][Medline]
  27. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR 1997 Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol Aging 18:457–461[CrossRef][Medline]
  28. Erecinska M, Bryla J, Michalik M, Meglasson MD, Nelson D 1992 Energy metabolism in islets of Langerhans. Biochim Biophys Acta 1101:273–295[CrossRef][Medline]
  29. Clark IA, Butcher GA, Buffinton GD, Hunt NH, Cowden WB 1987 Toxicity of certain products of lipid peroxidation to the human malaria parasite Plasmodium falciparum. Biochem Pharmacol 36:543–546[CrossRef][Medline]
  30. Novotny MV, Yancey MF, Stuart R, Wiesler D, Peterson RG 1994 Inhibition of glycolytic enzymes by endogenous aldehydes: a possible relation to diabetic neuropathies. Biochim Biophys Acta 1226:145–150[Medline]
  31. Cook DL, Hales CN 1984 Intracellular ATP directly blocks K+ channels in pancreatic B-cells. Nature 311:271–273[CrossRef][Medline]
  32. Misler S, Falke LC, Gillis K, McDaniel ML 1986 A metabolite-regulated potassium channel in rat pancreatic B cells. Proc Natl Acad Sci USA 83:7119–7123[Abstract/Free Full Text]
  33. Prentki M, Matschinsky FM 1987 Ca2+, cAMP and phospholipid derived messengers in coupling mechanisms of insulin secretion. Physiol Rev 67:1185–1248[Free Full Text]
  34. Giroix M-H, Saulnier C, Portha B 1999 Decreased pancreatic islet response to L-leucine in the spontaneously diabetic GK rat: enzymatic, metabolic and secretory data. Diabetologia 42:965–977[CrossRef][Medline]
  35. Malaisse WJ, Hutton JC, Carpinelli AR, Herchuelz A, Sener A 1980 The stimulus-secretion coupling of amino acid-induced insulin release. Metabolism and cationic effects of leucine. Diabetes 29:431–437[Abstract]
  36. Lenzen S, Schmidt W, Panten U 1985 Transamination of neutral amino acids and 2-keto acids in pancreatic B-cell mitochondria. J Biol Chem 260:12629–12634[Abstract/Free Full Text]
  37. Sener A, Malaisse WJ 1980 L-Leucine and a nonmetabolized analogue activate pancreatic islet glutamate dehydrogenase. Nature 288:187–189[CrossRef][Medline]
  38. Panten U, Zielmann S, Langer J. Zünkler B-J, Lenzen S 1984 Regulation of insulin secretion by energy metabolism in pancreatic B-cell mitochondria. Studies with a nonmetabolizable leucine analogue. Biochem J 219:189–196[Medline]
  39. DeFronzo RA 1988 The triumvirate: ß-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667–687[Medline]
  40. Ihara Y, Toyokuni S, Uchida K, Odaka H, Tanaka T, Ikeda H, Hiai H, Seino Y, Yamada Y 1999 Hyperglycemia causes oxidative stress in pancreatic ß-cells of GK rats, a model of type 2 diabetes. Diabetes 48:927–932[Abstract]



This article has been cited by other articles:


Home page
DiabetesHome page
D. Demozay, J.-C. Mas, S. Rocchi, and E. Van Obberghen
FALDH Reverses the Deleterious Action of Oxidative Stress Induced by Lipid Peroxidation Product 4-Hydroxynonenal on Insulin Signaling in 3T3-L1 Adipocytes
Diabetes, May 1, 2008; 57(5): 1216 - 1226.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. I. Oprescu, G. Bikopoulos, A. Naassan, E. M. Allister, C. Tang, E. Park, H. Uchino, G. F. Lewis, I. G. Fantus, M. Rozakis-Adcock, et al.
Free Fatty Acid Induced Reduction in Glucose-Stimulated Insulin Secretion: Evidence for a Role of Oxidative Stress In Vitro and In Vivo
Diabetes, December 1, 2007; 56(12): 2927 - 2937.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. Tang, P. Han, A. I. Oprescu, S. C. Lee, A. V. Gyulkhandanyan, G. N.Y. Chan, M. B. Wheeler, and A. Giacca
Evidence for a Role of Superoxide Generation in Glucose-Induced {beta}-Cell Dysfunction In Vivo
Diabetes, November 1, 2007; 56(11): 2722 - 2731.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. N. A. Hussain, G. Matar, E. Barreiro, M. Florian, M. Divangahi, and T. Vassilakopoulos
Modifications of proteins by 4-hydroxy-2-nonenal in the ventilatory muscles of rats
Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L996 - L1003.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
T. B. Mysore, T. A. Shinkel, J. Collins, E. J. Salvaris, N. Fisicaro, L. J. Murray-Segal, L. E.A. Johnson, D. A. Lepore, S. N. Walters, R. Stokes, et al.
Overexpression of Glutathione Peroxidase With Two Isoforms of Superoxide Dismutase Protects Mouse Islets From Oxidative Injury and Improves Islet Graft Function
Diabetes, July 1, 2005; 54(7): 2109 - 2116.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. J. MacDonald, R. D. Husain, S. Hoffmann-Benning, and T. R. Baker
Immunochemical Identification of Coenzyme Q0-Dihydrolipoamide Adducts in the E2 Components of the {alpha}-Ketoglutarate and Pyruvate Dehydrogenase Complexes Partially Explains the Cellular Toxicity of Coenzyme Q0
J. Biol. Chem., June 25, 2004; 279(26): 27278 - 27285.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky
Are Oxidative Stress-Activated Signaling Pathways Mediators of Insulin Resistance and {beta}-Cell Dysfunction?
Diabetes, January 1, 2003; 52(1): 1 - 8.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Endocr. Rev., October 1, 2002; 23(5): 599 - 622.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Deakin, I. Leviev, V. Nicaud, M.-C. B. Meynet, L. Tiret, and R. W. James
Paraoxonase-1 L55M Polymorphism Is Associated with an Abnormal Oral Glucose Tolerance Test and Differentiates High Risk Coronary Disease Families
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1268 - 1273.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miwa, I.
Right arrow Articles by Taniguchi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miwa, I.
Right arrow Articles by Taniguchi, S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals